{"transactions":[{"id":4638344,"issuer":{"id":184308,"kind":"organization","name":"TRex Bio, Inc.","symbol":"TRXB"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-09T01:50:38.000Z","date":"2026-10-08","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date."}],"balance_after":17500,"derivative":{"exercise_price":14,"expiration_date":"2036-10-08","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001193125-26-418292","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2139097/000119312526418292/ownership.xml","form_type":"4"}},{"id":747639,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:25:24.000Z","date":"2026-06-04","kind":"gift","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee."}],"balance_after":42000,"derivative":{"exercise_price":1.19,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001329959-26-000002","document":"form4-06052026_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000132995926000002/form4-06052026_080616.xml","form_type":"4"}},{"id":747638,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:25:24.000Z","date":"2026-06-04","kind":"gift","planned":false,"acquired":false,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":0,"derivative":{"exercise_price":1.19,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001329959-26-000002","document":"form4-06052026_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000132995926000002/form4-06052026_080616.xml","form_type":"4"}},{"id":747637,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:25:24.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":42000,"derivative":{"exercise_price":1.19,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001329959-26-000002","document":"form4-06052026_080616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000132995926000002/form4-06052026_080616.xml","form_type":"4"}},{"id":1113023,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-13T00:39:40.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":7828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024."}],"balance_after":33012,"source":{"system":"sec-edgar","filing":"0000905148-25-002142","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000090514825002142/form4.xml","form_type":"4"}},{"id":1117543,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:23:49.000Z","date":"2025-06-05","kind":"gift","planned":false,"acquired":true,"shares":33500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee."}],"balance_after":33500,"derivative":{"exercise_price":0.95,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":33500},"source":{"system":"sec-edgar","filing":"0001415889-25-016262","document":"form4-06092025_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000141588925016262/form4-06092025_080644.xml","form_type":"4"}},{"id":1117542,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:23:49.000Z","date":"2025-06-05","kind":"gift","planned":false,"acquired":false,"shares":33500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":0,"derivative":{"exercise_price":0.95,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":33500},"source":{"system":"sec-edgar","filing":"0001415889-25-016262","document":"form4-06092025_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000141588925016262/form4-06092025_080644.xml","form_type":"4"}},{"id":1117541,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:23:49.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":33500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":33500,"derivative":{"exercise_price":0.95,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":33500},"source":{"system":"sec-edgar","filing":"0001415889-25-016262","document":"form4-06092025_080644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000141588925016262/form4-06092025_080644.xml","form_type":"4"}},{"id":1484607,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:21:10.000Z","date":"2024-06-07","kind":"gift","planned":false,"acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee."}],"balance_after":67500,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0001415889-24-016208","document":"form4-06102024_080606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000141588924016208/form4-06102024_080606.xml","form_type":"4"}},{"id":1484606,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:21:10.000Z","date":"2024-06-07","kind":"gift","planned":false,"acquired":false,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0001415889-24-016208","document":"form4-06102024_080606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000141588924016208/form4-06102024_080606.xml","form_type":"4"}},{"id":1484605,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:21:10.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024."}],"balance_after":67500,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0001415889-24-016208","document":"form4-06102024_080606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000141588924016208/form4-06102024_080606.xml","form_type":"4"}},{"id":1552943,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-02T22:12:10.000Z","date":"2024-03-31","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amount includes an additional 20,190 shares that were previously inadvertently omitted from the Reporting Person's aggregate beneficial ownership."}],"balance_after":629608,"source":{"system":"sec-edgar","filing":"0000905148-24-001057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000090514824001057/form4.xml","form_type":"4"}},{"id":1672844,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:22.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":38.02,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":12784},"source":{"system":"sec-edgar","filing":"0001140361-24-003527","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036124003527/form4.xml","form_type":"4"}},{"id":1672843,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:37:22.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the \"Converted Cash Award\"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-003527","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036124003527/form4.xml","form_type":"4"}},{"id":1672842,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:37:22.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7555,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company (\"BMS\"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of January 23, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS."},{"field":"security","element":"securityTitle","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the \"Closing Consideration\") and (B) one contingent value right (a \"CVR\"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the \"Merger Consideration\"), without interest and subject to any withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units (\"RSUs\") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU."}],"balance_after":6808,"source":{"system":"sec-edgar","filing":"0001140361-24-003527","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036124003527/form4.xml","form_type":"4"}},{"id":1691372,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T23:27:38.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":6808,"price":58.75,"value":399970.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date."}],"balance_after":14363,"source":{"system":"sec-edgar","filing":"0001628280-24-000312","document":"wk-form4_1704324430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000162828024000312/wk-form4_1704324430.xml","form_type":"4"}},{"id":1740496,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-15T22:07:08.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":90980,"price":0.3098,"value":28185.604,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2862 to $0.3229."}],"balance_after":459418,"source":{"system":"sec-edgar","filing":"0000905148-23-001457","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000090514823001457/form4.xml","form_type":"4"}},{"id":1740495,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-11-15T22:07:08.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":179020,"price":0.2236,"value":40028.872,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.205 to $0.251. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4."}],"balance_after":368438,"source":{"system":"sec-edgar","filing":"0000905148-23-001457","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000090514823001457/form4.xml","form_type":"4"}},{"id":1844973,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-06-23T21:18:02.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":12784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option shall vest and become exercisable in 36 equal monthly installments following the date of grant."}],"balance_after":12784,"derivative":{"exercise_price":38.02,"expiration_date":"2023-06-22","underlying":"Common Stock","underlying_shares":12784},"source":{"system":"sec-edgar","filing":"0001628280-23-023351","document":"wk-form4_1687555072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000162828023023351/wk-form4_1687555072.xml","form_type":"4"}},{"id":1844972,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T21:18:02.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":7555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents a Restricted Stock Unit grant with a vesting period of 3 years that vests 33% annually from grant date."}],"balance_after":7555,"source":{"system":"sec-edgar","filing":"0001628280-23-023351","document":"wk-form4_1687555072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000162828023023351/wk-form4_1687555072.xml","form_type":"4"}},{"id":1858495,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T21:19:42.000Z","date":"2023-06-08","kind":"gift","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee."}],"balance_after":21500,"derivative":{"exercise_price":5.59,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-23-036383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919123036383/doc4.xml","form_type":"4"}},{"id":1858494,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T21:19:42.000Z","date":"2023-06-08","kind":"gift","planned":false,"acquired":false,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":0,"derivative":{"exercise_price":5.59,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-23-036383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919123036383/doc4.xml","form_type":"4"}},{"id":1858493,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T21:19:42.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":21500,"derivative":{"exercise_price":5.59,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-23-036383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919123036383/doc4.xml","form_type":"4"}},{"id":1869240,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2023-06-02T23:09:11.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":79500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":79500,"derivative":{"exercise_price":1.53,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":79500},"source":{"system":"sec-edgar","filing":"0001140361-23-028153","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036123028153/form4.xml","form_type":"4"}},{"id":1869239,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-02T23:09:11.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":189418,"source":{"system":"sec-edgar","filing":"0001140361-23-028153","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036123028153/form4.xml","form_type":"4"}},{"id":2104993,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2022-11-23T21:23:53.000Z","date":"2022-11-22","kind":"exercise","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol \"NAMS\"). The Business Combination closed on November 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol \"NAMS\"). The Business Combination closed on November 22, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol \"NAMS\"). The Business Combination closed on November 22, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol \"NAMS\"). The Business Combination closed on November 22, 2022."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-036923","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000089924322036923/doc4.xml","form_type":"4"}},{"id":2122092,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-11-08T21:22:36.000Z","date":"2022-11-05","kind":"gift","acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option  vest in 36 equal, monthly installments beginning on December 4, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee."}],"balance_after":39000,"derivative":{"exercise_price":11.28,"expiration_date":"2032-11-03","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001209191-22-056102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919122056102/doc4.xml","form_type":"4"}},{"id":2122091,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-11-08T21:22:36.000Z","date":"2022-11-05","kind":"gift","acquired":false,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option  vest in 36 equal, monthly installments beginning on December 4, 2022."}],"balance_after":39000,"derivative":{"exercise_price":11.28,"expiration_date":"2032-11-03","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001209191-22-056102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919122056102/doc4.xml","form_type":"4"}},{"id":2122090,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-11-08T21:22:36.000Z","date":"2022-11-04","kind":"grant","acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option  vest in 36 equal, monthly installments beginning on December 4, 2022."}],"balance_after":39000,"derivative":{"exercise_price":11.28,"expiration_date":"2032-11-03","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001209191-22-056102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919122056102/doc4.xml","form_type":"4"}},{"id":2180980,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:38:34.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":false,"nature":"By the Gallagher Revocable Trust dated May 10, 2011"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":39.99,"expiration_date":"2029-07-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-046284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919122046284/doc4.xml","form_type":"4"}},{"id":2180979,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:38:34.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":8500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":65.64,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-046284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919122046284/doc4.xml","form_type":"4"}},{"id":2180978,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:38:34.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":8500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":65.39,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-046284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919122046284/doc4.xml","form_type":"4"}},{"id":2220953,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2022-06-27T20:48:38.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":31500,"derivative":{"exercise_price":7.35,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001140361-22-024166","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036122024166/form4.xml","form_type":"4"}},{"id":2220952,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-27T20:48:38.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The amount of securities beneficially owned by the reporting person shown here corrects an inadvertent understatement of 100 shares in a prior Form 4."}],"balance_after":132418,"source":{"system":"sec-edgar","filing":"0001140361-22-024166","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036122024166/form4.xml","form_type":"4"}},{"id":2665817,"issuer":{"id":787,"kind":"organization","name":"Certara, Inc.","symbol":"CERT"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-16T12:48:34.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":7059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 7,059 restricted stock units (\"RSU\") granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual stockholder meeting."}],"balance_after":7059,"source":{"system":"sec-edgar","filing":"0001415889-21-003028","document":"form4-06162021_050625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000141588921003028/form4-06162021_050625.xml","form_type":"4"}},{"id":2675276,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2021-06-09T23:09:11.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":17500,"derivative":{"exercise_price":13.8,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001140361-21-020437","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036121020437/form4.xml","form_type":"4"}},{"id":2675275,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-09T23:09:11.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":111818,"source":{"system":"sec-edgar","filing":"0001140361-21-020437","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000114036121020437/form4.xml","form_type":"4"}},{"id":2680576,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-04T21:39:10.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the one-year anniversary of the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":65.64,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-21-038333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919121038333/doc4.xml","form_type":"4"}},{"id":3101702,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-23T11:07:09.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date."}],"balance_after":12000,"derivative":{"exercise_price":2.4,"expiration_date":"2030-06-21","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001544227-20-000033","document":"wf-form4_159291041152553.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000154422720000033/wf-form4_159291041152553.xml","form_type":"4"}},{"id":3106591,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-17T22:47:44.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest on the one-year anniversary of the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":65.39,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-20-037410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919120037410/doc4.xml","form_type":"4"}},{"id":3106590,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-17T22:47:44.000Z","date":"2019-08-27","kind":"gift","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Gallagher Revocable Trust dated May 10, 2011"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":39.99,"expiration_date":"2029-07-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-037410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919120037410/doc4.xml","form_type":"4"}},{"id":3106589,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-17T22:47:44.000Z","date":"2019-08-27","kind":"gift","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person contributed this option, for no consideration, to a trust for the benefit of the Reporting Person. The Reporting Person remains the beneficial owner of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant."}],"balance_after":0,"derivative":{"exercise_price":39.99,"expiration_date":"2029-07-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-037410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919120037410/doc4.xml","form_type":"4"}},{"id":3106588,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2020-06-17T21:46:04.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":24500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":24500,"derivative":{"exercise_price":10.54,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":24500},"source":{"system":"sec-edgar","filing":"0001209191-20-037367","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919120037367/doc4.xml","form_type":"4"}},{"id":3106587,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-17T21:46:04.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":100818,"source":{"system":"sec-edgar","filing":"0001209191-20-037367","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919120037367/doc4.xml","form_type":"4"}},{"id":3455835,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-07-25T20:12:55.000Z","date":"2019-07-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":39.99,"expiration_date":"2029-07-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-043220","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919119043220/doc4.xml","form_type":"4"}},{"id":3474446,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2019-07-01T21:00:35.000Z","date":"2019-06-27","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":13000,"derivative":{"exercise_price":20.25,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-19-039767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919119039767/doc4.xml","form_type":"4"}},{"id":3474445,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T21:00:35.000Z","date":"2019-06-27","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":92818,"source":{"system":"sec-edgar","filing":"0001209191-19-039767","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919119039767/doc4.xml","form_type":"4"}},{"id":3481022,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-21T20:35:04.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":12000,"derivative":{"exercise_price":11.59,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-038479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919119038479/doc4.xml","form_type":"4"}},{"id":3692685,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-17T21:46:06.000Z","date":"2019-01-15","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date."}],"balance_after":6000,"derivative":{"exercise_price":8.8,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-19-004235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919119004235/doc4.xml","form_type":"4"}},{"id":3735265,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-12T00:38:48.000Z","date":"2018-12-07","kind":"grant","acquired":true,"shares":23684,"ownership":{"direct":false,"nature":"By: Gallagher Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 318,335 shares of Millendo Therapeutics, Inc. common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer."}],"balance_after":23684,"source":{"system":"sec-edgar","filing":"0001209191-18-062111","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118062111/doc4.xml","form_type":"4"}},{"id":3735264,"issuer":{"id":7734,"kind":"organization","name":"Tempest Therapeutics, Inc."},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-12T00:38:48.000Z","date":"2018-12-07","kind":"grant","acquired":true,"shares":8249,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 110,887 shares of Millendo Therapeutics, Inc. common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer."}],"balance_after":8249,"source":{"system":"sec-edgar","filing":"0001209191-18-062111","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118062111/doc4.xml","form_type":"4"}},{"id":3771386,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-08T00:44:51.000Z","date":"2018-11-07","kind":"sale","acquired":false,"shares":21374,"price":36.38,"value":777586.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.87 to $36.84. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":88818,"source":{"system":"sec-edgar","filing":"0001209191-18-057696","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118057696/doc4.xml","form_type":"4"}},{"id":3888208,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-19T20:35:06.000Z","date":"2018-06-18","kind":"sale","acquired":false,"shares":400,"price":45.29,"value":18116.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.25 to $45.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":110192,"source":{"system":"sec-edgar","filing":"0001209191-18-038568","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118038568/doc4.xml","form_type":"4"}},{"id":3888207,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-19T20:35:06.000Z","date":"2018-06-18","kind":"sale","acquired":false,"shares":2100,"price":44.68,"value":93828.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.10 to $45.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":110592,"source":{"system":"sec-edgar","filing":"0001209191-18-038568","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118038568/doc4.xml","form_type":"4"}},{"id":3890419,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2018-06-18T20:28:12.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on June 14, 2019, subject to the Reporting Person's continuous service."}],"balance_after":5000,"derivative":{"exercise_price":45.65,"expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-18-038309","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118038309/doc4.xml","form_type":"4"}},{"id":3890418,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-18T20:28:12.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on June 14, 2019, subject to the Reporting Person's continuous service."}],"balance_after":112692,"source":{"system":"sec-edgar","filing":"0001209191-18-038309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118038309/doc4.xml","form_type":"4"}},{"id":3930437,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-05-17T00:37:54.000Z","date":"2018-05-15","kind":"exercise","acquired":false,"shares":545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The earlier of (i) March 27, 2021 or (ii) the recipient's termination date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":545},"source":{"system":"sec-edgar","filing":"0001209191-18-030723","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118030723/doc4.xml","form_type":"4"}},{"id":3930436,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-17T00:37:54.000Z","date":"2018-05-16","kind":"sale","acquired":false,"shares":273,"price":46.06,"value":12574.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."}],"balance_after":111192,"source":{"system":"sec-edgar","filing":"0001209191-18-030723","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118030723/doc4.xml","form_type":"4"}},{"id":3930435,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-17T00:37:54.000Z","date":"2018-05-15","kind":"exercise","acquired":true,"shares":545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":111465,"source":{"system":"sec-edgar","filing":"0001209191-18-030723","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118030723/doc4.xml","form_type":"4"}},{"id":4047010,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-02-21T01:25:40.000Z","date":"2018-02-15","kind":"exercise","acquired":false,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 27, 2021 or (ii) the recipient's termination date."}],"balance_after":545,"derivative":{"underlying":"Common Stock","underlying_shares":817},"source":{"system":"sec-edgar","filing":"0001209191-18-011674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118011674/doc4.xml","form_type":"4"}},{"id":4047009,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-02-21T01:25:40.000Z","date":"2018-02-15","kind":"exercise","acquired":false,"shares":1548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1548},"source":{"system":"sec-edgar","filing":"0001209191-18-011674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118011674/doc4.xml","form_type":"4"}},{"id":4047008,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-21T01:25:40.000Z","date":"2018-02-16","kind":"sale","acquired":false,"shares":1183,"price":46.5,"value":55009.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."}],"balance_after":110920,"source":{"system":"sec-edgar","filing":"0001209191-18-011674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118011674/doc4.xml","form_type":"4"}},{"id":4047007,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-21T01:25:40.000Z","date":"2018-02-15","kind":"exercise","acquired":true,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":112103,"source":{"system":"sec-edgar","filing":"0001209191-18-011674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118011674/doc4.xml","form_type":"4"}},{"id":4047006,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-21T01:25:40.000Z","date":"2018-02-15","kind":"exercise","acquired":true,"shares":1548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":111286,"source":{"system":"sec-edgar","filing":"0001209191-18-011674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118011674/doc4.xml","form_type":"4"}},{"id":4073476,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-02-06T21:09:23.000Z","date":"2018-02-02","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":6000,"derivative":{"exercise_price":104.81,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-18-007828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919118007828/doc4.xml","form_type":"4"}},{"id":4157768,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-11-17T23:24:13.000Z","date":"2017-11-15","kind":"exercise","acquired":false,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 27, 2021 or (ii) the recipient's termination date."}],"balance_after":1362,"derivative":{"underlying":"Common Stock","underlying_shares":817},"source":{"system":"sec-edgar","filing":"0001209191-17-061600","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117061600/doc4.xml","form_type":"4"}},{"id":4157767,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-11-17T23:24:13.000Z","date":"2017-11-15","kind":"exercise","acquired":false,"shares":1549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date."}],"balance_after":1548,"derivative":{"underlying":"Common Stock","underlying_shares":1549},"source":{"system":"sec-edgar","filing":"0001209191-17-061600","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117061600/doc4.xml","form_type":"4"}},{"id":4157766,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-17T23:24:13.000Z","date":"2017-11-16","kind":"sale","acquired":false,"shares":1184,"price":14.2,"value":16812.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."}],"balance_after":109738,"source":{"system":"sec-edgar","filing":"0001209191-17-061600","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117061600/doc4.xml","form_type":"4"}},{"id":4157765,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-17T23:24:13.000Z","date":"2017-11-15","kind":"exercise","acquired":true,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":110922,"source":{"system":"sec-edgar","filing":"0001209191-17-061600","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117061600/doc4.xml","form_type":"4"}},{"id":4157764,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-17T23:24:13.000Z","date":"2017-11-15","kind":"exercise","acquired":true,"shares":1549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":110105,"source":{"system":"sec-edgar","filing":"0001209191-17-061600","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117061600/doc4.xml","form_type":"4"}},{"id":4230436,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-08-17T21:38:54.000Z","date":"2017-08-15","kind":"exercise","acquired":false,"shares":818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 27, 2021 or (ii) the recipient's termination date."}],"balance_after":2179,"derivative":{"underlying":"Common Stock","underlying_shares":818},"source":{"system":"sec-edgar","filing":"0001209191-17-049452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117049452/doc4.xml","form_type":"4"}},{"id":4230435,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-08-17T21:38:54.000Z","date":"2017-08-15","kind":"exercise","acquired":false,"shares":1548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date."}],"balance_after":3097,"derivative":{"underlying":"Common Stock","underlying_shares":1548},"source":{"system":"sec-edgar","filing":"0001209191-17-049452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117049452/doc4.xml","form_type":"4"}},{"id":4230434,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-17T21:38:54.000Z","date":"2017-08-16","kind":"sale","acquired":false,"shares":1184,"price":14.3,"value":16931.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."}],"balance_after":108556,"source":{"system":"sec-edgar","filing":"0001209191-17-049452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117049452/doc4.xml","form_type":"4"}},{"id":4230433,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-17T21:38:54.000Z","date":"2017-08-15","kind":"exercise","acquired":true,"shares":818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":109740,"source":{"system":"sec-edgar","filing":"0001209191-17-049452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117049452/doc4.xml","form_type":"4"}},{"id":4230432,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-17T21:38:54.000Z","date":"2017-08-15","kind":"exercise","acquired":true,"shares":1548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":108922,"source":{"system":"sec-edgar","filing":"0001209191-17-049452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117049452/doc4.xml","form_type":"4"}},{"id":4285210,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2017-06-12T21:29:14.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service."}],"balance_after":21500,"derivative":{"exercise_price":13.2,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-17-039239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117039239/doc4.xml","form_type":"4"}},{"id":4285209,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-12T21:29:14.000Z","date":"2017-06-09","kind":"sale","acquired":false,"shares":1000,"price":13.15,"value":13150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."}],"balance_after":107374,"source":{"system":"sec-edgar","filing":"0001209191-17-039239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117039239/doc4.xml","form_type":"4"}},{"id":4285208,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-12T21:29:14.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on June 8, 2018, subject to the Reporting Person's continuous service."}],"balance_after":108374,"source":{"system":"sec-edgar","filing":"0001209191-17-039239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117039239/doc4.xml","form_type":"4"}},{"id":4315316,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-05-17T21:01:11.000Z","date":"2017-05-15","kind":"exercise","acquired":false,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 27, 2021 or (ii) the recipient's termination date."}],"balance_after":2997,"derivative":{"underlying":"Common Stock","underlying_shares":817},"source":{"system":"sec-edgar","filing":"0001209191-17-033206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117033206/doc4.xml","form_type":"4"}},{"id":4315315,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-05-17T21:01:11.000Z","date":"2017-05-15","kind":"exercise","acquired":false,"shares":1549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date."}],"balance_after":4645,"derivative":{"underlying":"Common Stock","underlying_shares":1549},"source":{"system":"sec-edgar","filing":"0001209191-17-033206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117033206/doc4.xml","form_type":"4"}},{"id":4315314,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-17T21:01:11.000Z","date":"2017-05-16","kind":"sale","acquired":false,"shares":1184,"price":15.25,"value":18056.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."}],"balance_after":103374,"source":{"system":"sec-edgar","filing":"0001209191-17-033206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117033206/doc4.xml","form_type":"4"}},{"id":4315313,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-17T21:01:11.000Z","date":"2017-05-15","kind":"exercise","acquired":true,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":104558,"source":{"system":"sec-edgar","filing":"0001209191-17-033206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117033206/doc4.xml","form_type":"4"}},{"id":4315312,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-17T21:01:11.000Z","date":"2017-05-15","kind":"exercise","acquired":true,"shares":1549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":103741,"source":{"system":"sec-edgar","filing":"0001209191-17-033206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117033206/doc4.xml","form_type":"4"}},{"id":4417040,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-02-28T23:53:11.000Z","date":"2017-02-24","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes fully exercisable on February 24, 2018."}],"balance_after":15000,"derivative":{"exercise_price":24.6,"expiration_date":"2027-02-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-015458","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117015458/doc4.xml","form_type":"4"}},{"id":4442199,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-02-17T01:12:12.000Z","date":"2017-02-15","kind":"exercise","acquired":false,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 27, 2021 or (ii) the recipient's termination date."}],"balance_after":3814,"derivative":{"underlying":"Common Stock","underlying_shares":817},"source":{"system":"sec-edgar","filing":"0001209191-17-011769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117011769/doc4.xml","form_type":"4"}},{"id":4442198,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-02-17T01:12:12.000Z","date":"2017-02-15","kind":"exercise","acquired":false,"shares":1548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date."}],"balance_after":6194,"derivative":{"underlying":"Common Stock","underlying_shares":1548},"source":{"system":"sec-edgar","filing":"0001209191-17-011769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117011769/doc4.xml","form_type":"4"}},{"id":4442197,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-17T01:12:12.000Z","date":"2017-02-16","kind":"sale","acquired":false,"shares":1183,"price":16.1,"value":19046.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."}],"balance_after":102192,"source":{"system":"sec-edgar","filing":"0001209191-17-011769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117011769/doc4.xml","form_type":"4"}},{"id":4442196,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-17T01:12:12.000Z","date":"2017-02-15","kind":"exercise","acquired":true,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":103375,"source":{"system":"sec-edgar","filing":"0001209191-17-011769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117011769/doc4.xml","form_type":"4"}},{"id":4442195,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-17T01:12:12.000Z","date":"2017-02-15","kind":"exercise","acquired":true,"shares":1548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":102558,"source":{"system":"sec-edgar","filing":"0001209191-17-011769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117011769/doc4.xml","form_type":"4"}},{"id":4475057,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2017-01-31T21:50:45.000Z","date":"2017-01-31","kind":"exercise","acquired":false,"shares":21439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":21439},"source":{"system":"sec-edgar","filing":"0001209191-17-006405","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117006405/doc4.xml","form_type":"4"}},{"id":4475056,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-01-31T21:50:45.000Z","date":"2017-01-31","kind":"exercise","acquired":false,"shares":42857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42857},"source":{"system":"sec-edgar","filing":"0001209191-17-006405","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117006405/doc4.xml","form_type":"4"}},{"id":4475055,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-31T21:50:45.000Z","date":"2017-01-31","kind":"exercise","acquired":true,"shares":64296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated."}],"balance_after":64296,"source":{"system":"sec-edgar","filing":"0001209191-17-006405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117006405/doc4.xml","form_type":"4"}},{"id":4497913,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2017-01-05T21:20:16.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on June 8, 2017, the date of the Company's annual stockholder meeting, subject to the Reporting Person's continuous service."}],"balance_after":5500,"derivative":{"exercise_price":15.08,"expiration_date":"2024-01-03","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001209191-17-002058","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117002058/doc4.xml","form_type":"4"}},{"id":4497912,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-05T21:20:16.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on June 8, 2017, the date of the Company's annual stockholder meeting, subject to the Reporting Person's continuous service."}],"balance_after":101010,"source":{"system":"sec-edgar","filing":"0001209191-17-002058","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919117002058/doc4.xml","form_type":"4"}},{"id":4550030,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2016-11-17T21:51:27.000Z","date":"2016-11-15","kind":"exercise","acquired":false,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from March 25, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) March 27, 2021 or (ii) the recipient's termination date."}],"balance_after":4631,"derivative":{"underlying":"Common Stock","underlying_shares":817},"source":{"system":"sec-edgar","filing":"0001209191-16-150910","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919116150910/doc4.xml","form_type":"4"}},{"id":4550029,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2016-11-17T21:51:27.000Z","date":"2016-11-15","kind":"exercise","acquired":false,"shares":1549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units (\"RSUs\") were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through August 17, 2015, were settled on August 17, 2015. The service-based vesting condition provides that 1/48th of the total number of shares vest monthly from January 30, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The earlier of (i) January 30, 2021 or (ii) the second anniversary of termination date."}],"balance_after":7742,"derivative":{"underlying":"Common Stock","underlying_shares":1549},"source":{"system":"sec-edgar","filing":"0001209191-16-150910","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919116150910/doc4.xml","form_type":"4"}},{"id":4550028,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-17T21:51:27.000Z","date":"2016-11-16","kind":"sale","acquired":false,"shares":1184,"price":19.35,"value":22910.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted October 14, 2016."}],"balance_after":99010,"source":{"system":"sec-edgar","filing":"0001209191-16-150910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919116150910/doc4.xml","form_type":"4"}},{"id":4550027,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-17T21:51:27.000Z","date":"2016-11-15","kind":"exercise","acquired":true,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":100194,"source":{"system":"sec-edgar","filing":"0001209191-16-150910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919116150910/doc4.xml","form_type":"4"}},{"id":4550026,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":40847,"kind":"person","name":"Gallagher Carol Giltner","position":1,"cik":"0001329959","reported_name":"Gallagher Carol Giltner","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-11-17T21:51:27.000Z","date":"2016-11-15","kind":"exercise","acquired":true,"shares":1549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units."}],"balance_after":99377,"source":{"system":"sec-edgar","filing":"0001209191-16-150910","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1329959/000120919116150910/doc4.xml","form_type":"4"}}]}